Thrombophilia in patients with retinal vein occlusion: a retrospective analysis.
BACKGROUND
To assess the prevalence of thrombophilia in patients with central (CRVO) and branch retinal vein occlusion (BRVO).


METHODS
In 139 patients with CRVO (n = 88) and BRVO (n = 51) and in 40 healthy controls factor VIII, fibrinogen, antithrombin III, protein C, protein S, activated protein C resistance, anticardiolipin antibodies (ACA), homocysteine, factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T mutation were assessed retrospectively.


RESULTS
Elevated factor VIII activity and the homozygous MTHFR C677T mutation were significantly more often found in CRVO and BRVO cases compared to controls. Age-, gender- and C-reactive protein-adjusted logistic regression analysis did not show a significant additive effect of elevated factor VIII activity on the risk of developing CRVO/BRVO. Elevated fibrinogen levels and ACA were significantly more often found in CRVO than amongst controls. No significant differences were found concerning the remaining variables.


CONCLUSIONS
We suggest elevated fibrinogen levels, ACA and the homozygous MTHFR C677T mutation as potential risk factors for CRVO/BRVO.
Department of Ophthalmology, RWTH Aachen University, Aachen, Germany.
Franziska
F
Risse
Rolf Dario
RD
Frank
Andreas W A
AW
Weinberger
D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000097:blood; D015415:Biomarkers / Q000378:metabolism; D005260:Female; D005340:Fibrinogen; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D015995:Prevalence; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000175:diagnosis; D012189:Retrospective Studies; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000209:etiology*
D017153:Antibodies, Anticardiolipin; D015415:Biomarkers; D005340:Fibrinogen; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2)